Plagued By Controversy, Promising Alzheimer's Treatment, 2024 To Be Pivotal For Cassava Sciences

 
• By David Wild

All eyes will be on Cassava Sciences in 2024, as it completes two Phase III trials of its closely watched Alzheimer’s disease candidate, simufilam. The drug has been the subject of both skepticism and enthusiasm. 

Cassava Sciences's Phase III Results Will Be Closely Watched In The Year Ahead • Source: Shutterstock

More from Market Intelligence

More from In Vivo